Implementation of therapeutic guidelines for mucopolysaccharidosis IVA and VI in public health institutions in Brazil: real-world challenges and opportunities
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Mucopolysaccharidoses (MPS) IVA and VI are rare, progressive disorders for which enzyme replacement therapy (ERT) and regular clinical monitoring are recommended to optimize outcomes. However, in public health systems such as Brazil's Unified Health System (SUS), the real-world implementation of therapeutic guidelines remains challenging and insufficiently documented. Objective This study aims to analyze the challenges and opportunities in implementing therapeutic guidelines for Mucopolysaccharidosis (MPS) IVA and VI in Brazil, focusing on clinical monitoring and treatment adherence within public healthcare institutions. Methods This Phase 4, non-interventional, multicenter prospective cohort study was conducted across nine Brazilian institutions. Medical chart data covering up to 3 years were collected from participants receiving enzyme replacement therapy (ERT) with elosulfase alfa or galsulfase through the Unified Health System (SUS). Variables included demographics, treatment exposure, adherence, the number and reasons for not performing clinical and functional assessments (urinary glycosaminoglycans, pulmonary function tests, 6-minute walk test, and quality of life scales). Adherence was calculated as the proportion of infusions received vs. those expected. Results Twenty participants were enrolled (11 MPS IVA; nine MPS VI), with median ages of 9.0 and 3.0 years and mean ERT exposure of 1.3 and 1.6 years, respectively. Clinical and functional assessments were largely incomplete at baseline and remained inconsistent throughout follow-up. Although exam frequency increased, particularly in MPS IVA, monitoring remained irregular in both cohorts. The main reasons for missed assessments were lack of physician request, equipment unavailability, logistical barriers, and patient limitations; several tests were also considered not applicable due to age or clinical condition. Overall, operational constraints are limited to standardized clinical and functional monitoring. Conclusion MPS care guidelines are formally established in Brazil, but their full implementation is limited by inconsistent clinical monitoring due to operational constraints. Reducing logistical barriers and standardizing follow-up protocols may enhance patient outcomes and support long-term access to high-cost therapies in the public health system.
Source: Frontiers in Public Health
Institutions: Instituto de Medicina Integral Professor Fernando Figueira, Universidade Federal de São Paulo, Universidade Federal do Pará, Universidade de São Paulo, Universidade Federal de Campina Grande, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Casa dos Raros
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Keywords: mucopolysaccharidosis type IVA, mucopolysaccharidosis type VI, enzyme replacement therapy, elosulfase alfa, galsulfase, medication adherence, patient monitoring, guideline implementation, public health system, Unified Health System (SUS), rare diseases, glycosaminoglycans, pulmonary function tests, 6-minute walk test, quality of life, Brazil
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235338835
